Overview

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

LG Life Sciences

Treatments:

Metformin